QYUNS-B (02509) announced its results for the six months ended June 30, 2025. The group achieved revenue of RMB 206 million, representing a year-on-year increase of 359.69%. R&D expenses totaled RMB 151 million, up 4.25% compared to the same period last year. The company recorded a loss of RMB 30.933 million for the period, a decrease of 83.11% year-on-year, with loss per share of RMB 0.13.

For the six months ended June 30, 2025, the group's revenue of RMB 206 million primarily comprised income from licensing agreements, including upfront payments related to overseas licensing of QX030N and non-cash consideration for approximately 24.88% equity stake in Caldera Therapeutics, Inc., as well as milestone payments for the first patient enrollment in QX004N Phase III trial, totaling RMB 181 million. Additionally, the company generated approximately RMB 22 million from CDMO services and R&D services provided for QX004N and QX008N projects.

The company's R&D expenses increased by 4.25% from RMB 145 million for the six months ended June 30, 2024, to RMB 151 million for the six months ended June 30, 2025. This included a decrease of RMB 5.87 million in equity-settled share-based payment amortization, while R&D expenditure increased by RMB 12.04 million, primarily due to higher clinical trial costs resulting from the advancement of the company's clinical trials.